195 related articles for article (PubMed ID: 30702598)
1. Intraperitoneal infusion of ex vivo-cultured allogeneic NK cells in recurrent ovarian carcinoma patients (a phase I study).
Hoogstad-van Evert J; Bekkers R; Ottevanger N; Schaap N; Hobo W; Jansen JH; Massuger L; Dolstra H
Medicine (Baltimore); 2019 Feb; 98(5):e14290. PubMed ID: 30702598
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer.
Geller MA; Cooley S; Judson PL; Ghebre R; Carson LF; Argenta PA; Jonson AL; Panoskaltsis-Mortari A; Curtsinger J; McKenna D; Dusenbery K; Bliss R; Downs LS; Miller JS
Cytotherapy; 2011 Jan; 13(1):98-107. PubMed ID: 20849361
[TBL] [Abstract][Full Text] [Related]
3. High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy.
Spanholtz J; Tordoir M; Eissens D; Preijers F; van der Meer A; Joosten I; Schaap N; de Witte TM; Dolstra H
PLoS One; 2010 Feb; 5(2):e9221. PubMed ID: 20169160
[TBL] [Abstract][Full Text] [Related]
4. Natural killer cells generated from cord blood hematopoietic progenitor cells efficiently target bone marrow-residing human leukemia cells in NOD/SCID/IL2Rg(null) mice.
Cany J; van der Waart AB; Tordoir M; Franssen GM; Hangalapura BN; de Vries J; Boerman O; Schaap N; van der Voort R; Spanholtz J; Dolstra H
PLoS One; 2013; 8(6):e64384. PubMed ID: 23755121
[TBL] [Abstract][Full Text] [Related]
5. Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients.
Szmania S; Lapteva N; Garg T; Greenway A; Lingo J; Nair B; Stone K; Woods E; Khan J; Stivers J; Panozzo S; Campana D; Bellamy WT; Robbins M; Epstein J; Yaccoby S; Waheed S; Gee A; Cottler-Fox M; Rooney C; Barlogie B; van Rhee F
J Immunother; 2015 Jan; 38(1):24-36. PubMed ID: 25415285
[TBL] [Abstract][Full Text] [Related]
6. Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model.
Geller MA; Knorr DA; Hermanson DA; Pribyl L; Bendzick L; McCullar V; Miller JS; Kaufman DS
Cytotherapy; 2013 Oct; 15(10):1297-306. PubMed ID: 23993303
[TBL] [Abstract][Full Text] [Related]
7. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
[TBL] [Abstract][Full Text] [Related]
8. Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation.
Shaffer BC; Le Luduec JB; Forlenza C; Jakubowski AA; Perales MA; Young JW; Hsu KC
Biol Blood Marrow Transplant; 2016 Apr; 22(4):705-709. PubMed ID: 26772158
[TBL] [Abstract][Full Text] [Related]
9. Protective role of functionalized single walled carbon nanotubes enhance ex vivo expansion of hematopoietic stem and progenitor cells in human umbilical cord blood.
Bari S; Chu PP; Lim A; Fan X; Gay FP; Bunte RM; Lim TK; Li S; Chiu GN; Hwang WY
Nanomedicine; 2013 Nov; 9(8):1304-16. PubMed ID: 23732300
[TBL] [Abstract][Full Text] [Related]
10. The phenotypic and functional characteristics of umbilical cord blood and peripheral blood natural killer cells.
Verneris MR; Miller JS
Br J Haematol; 2009 Oct; 147(2):185-91. PubMed ID: 19796267
[TBL] [Abstract][Full Text] [Related]
11. Ex vivo expansion of T, NK and CD34+ cells from umbilical cord blood.
Wei YM; Cao Q; Zhou HY; Xia R; Lan JC; Meng FY; Bai H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Dec; 13(6):1076-81. PubMed ID: 16403284
[TBL] [Abstract][Full Text] [Related]
12. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial.
Arai S; Meagher R; Swearingen M; Myint H; Rich E; Martinson J; Klingemann H
Cytotherapy; 2008; 10(6):625-32. PubMed ID: 18836917
[TBL] [Abstract][Full Text] [Related]
13. Ex vivo-expanded NK cells from blood and ascites of ovarian cancer patients are cytotoxic against autologous primary ovarian cancer cells.
Nham T; Poznanski SM; Fan IY; Shenouda MM; Chew MV; Lee AJ; Vahedi F; Karimi Y; Butcher M; Lee DA; Hirte H; Ashkar AA
Cancer Immunol Immunother; 2018 Apr; 67(4):575-587. PubMed ID: 29299659
[TBL] [Abstract][Full Text] [Related]
14. Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process.
Spanholtz J; Preijers F; Tordoir M; Trilsbeek C; Paardekooper J; de Witte T; Schaap N; Dolstra H
PLoS One; 2011; 6(6):e20740. PubMed ID: 21698239
[TBL] [Abstract][Full Text] [Related]
15. Phase I non-randomized clinical trial of allogeneic natural killer cells infusion in acute myeloid leukemia patients.
Ahmadvand M; Barough MS; Barkhordar M; Faridfar A; Ghaderi A; Jalaeikhoo H; Rajaienejad M; Majidzadeh K; Ghavamzadeh A; Sarrami-Forooshani R
BMC Cancer; 2023 Nov; 23(1):1090. PubMed ID: 37950209
[TBL] [Abstract][Full Text] [Related]
16. Influence of the mesenchymal stromal cell source on the hematopoietic supportive capacity of umbilical cord blood-derived CD34
Bucar S; Branco ADM; Mata MF; Milhano JC; Caramalho Í; Cabral JMS; Fernandes-Platzgummer A; da Silva CL
Stem Cell Res Ther; 2021 Jul; 12(1):399. PubMed ID: 34256848
[TBL] [Abstract][Full Text] [Related]
17. Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III/IV) pancreatic cancer: a promising treatment.
Lin M; Liang S; Wang X; Liang Y; Zhang M; Chen J; Niu L; Xu K
J Cancer Res Clin Oncol; 2017 Dec; 143(12):2607-2618. PubMed ID: 28871458
[TBL] [Abstract][Full Text] [Related]
18. Gynecological malignancies.
Schaebler DL; Schilder RJ; Young RC
Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
[TBL] [Abstract][Full Text] [Related]
19. Harnessing natural killer cells for the treatment of ovarian cancer.
Hoogstad-van Evert JS; Bekkers R; Ottevanger N; Jansen JH; Massuger L; Dolstra H
Gynecol Oncol; 2020 Jun; 157(3):810-816. PubMed ID: 32268953
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxic function of umbilical cord blood natural killer cells: relevance to adoptive immunotherapy.
Lin SJ; Kuo ML
Pediatr Hematol Oncol; 2011 Nov; 28(8):640-6. PubMed ID: 21970456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
